The Status of Serum Amylase among type 2 Diabetes Patients in Pokhara
Introduction: Diabetes Mellitus has become one of the common metabolic disorders characterized by hyperglycemia, associated with deficiency or resistance to insulin and shows abnormality in exocrine activity of pancreas. Pancreas is mixed gland that is both an endocrine and an exocrine gland with clusters of endocrinal, islet cell dispersed among exocrine acinar cells. Defects in islets cells in diabetes effect the exocrine secretion of the pancreas.
Methods: Hospital based case-control study was conducted. Total sample size was 388. Out of which 194 were known cases of type 2 diabetic patients attending Manipal Teaching Hospital for medical checkup whereas 194 were Non Diabetic individuals with age and sex matched. Self-administer question was used to collected data from case and control. Three ml fasting blood samples were collected and centrifuged. Serum amylase was analyzed by using a semi automated analyzer. All estimates data were analysis statistically by using SPSS 22.0 full version.
Results: Serum amylase levels were found significantly low in diabetic patients as compared to the Non-Diabetic
(r = -0.313, p-value <0.001). Similarly, present study also showed negative correlation between serum amylase levels and duration of diabetes with Non-Diabetic (r = -0.388, p <0.001). Status of serum amylase and fasting sugar level was found to different among age groups, sex and ethnic groups.
Conclusions: The increasing in duration of diabetes decreases the level of serum amylase which suggests a possible exocrine-endocrine relationship in this disease. Similarly, the level of serum amylase and fasting blood sugar vary among age group, sex and ethnicity. Thus, measurement of serum amylase can be an additional informative parameter for the assessment of chronicity and progress of the illness as well as the response to therapy.
Copyright (c) 2020 Journal of Health and Allied Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.